Category: Business

Second Sight Receives Conditional FDA Approval to Begin First Orion Human Clinical Study

SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide useful vision to blind patients, today announced that the Company has received conditional approval from the U.S. Food and Drug Administration (FDA) to begin the Orion™ Cortical Visual Prosthesis System (Orion) feasibility clinical study. The conditional approval allows two U.S. sites to enroll u

Aerie Pharmaceuticals Announces Appointment of Deanne Melloy as Vice President of Marketing and Norbert Lowe as Regional Sales Director

IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of Deanne Melloy as Vice President of Marketing, reporting to Judith Robertson, Aerie’s Chief Commercial Officer. Aerie also announced the appointment of Norbert Lowe as Regional Sales Director for the

Aerie Pharmaceuticals Announces Appointment of Isabel Moredo, PharmD, as Eastern Regional Director of Medical Science Liaisons

IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of Isabel Moredo, PharmD, as Eastern Regional Director of Medical Science Liaisons, reporting to Welyn Bui, PharmD, Aerie’s National Director of Medical Affairs. Dr. Moredo will be responsible for leadi

NovaBay Pharmaceuticals Reports Second Quarter 2017 Financial Results

EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for lid and lash hygiene in the domestic eye care market, reports financial results for the three and six months ended June 30, 2017 and provides a business update. “We had record Avenova unit volume through the pharmacy channel during the second quarter, along with an 80% increase in revenue through this channel over the prior year.

Aerpio Pharmaceuticals Commences Trading on the OTCQB® Market

CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, announced today that shares of the Company’s common stock have been cleared for trading on the OTC Market Group’s OTCQB® Market (“OTCQB”) in the United States. Shares of Aerpio’s common stock will trade under the ticker symbol “ARPO”, effective at the market open on August 8, 2017. In March 2017, Aerpio raised approximately $40 m